Inspire Medical’s V System Achieves 20.4% Faster Implants and 25.5 AHI Reduction
INSP•Inspire Medical announced data showing its Inspire V system achieved 20.4% faster implant times, a 25.5‐event per hour AHI decline and 5.9‐hour usage in 44 patients. The PREDICTOR study identified BMI and neck circumference as predictors of complete concentric collapse, potentially reducing diagnostic burden and accelerating treatment.
1. SLEEP 2026 Participation
Inspire Medical presented at SLEEP 2026, showcasing the Inspire V system, closed-loop respiratory sensing technology and the SleepSync remote patient management platform. The company hosted sessions on hypoglossal nerve stimulation and cardiovascular outcomes, offering physicians resources for expanding Inspire programs globally.
2. Inspire V System Advancements
Data from 44 participants implanted with the Inspire V system revealed a 20.4% reduction in implant procedure times compared to the prior generation and a mean AHI decrease of 25.5 events per hour. Patients recorded an average nightly therapy usage of 5.9 hours, with respiratory sensing demonstrating 87.1% inspiratory phase overlap versus 79.4% previously.
3. Hypoxic Burden and Cardiovascular Outcomes
A secondary analysis of the STAR trial showed significant hypoxic burden reductions and daytime sleepiness improvements in at least half of AHI non-responders, reinforcing hypoxic burden as a key biomarker. A TriNetX database study of 3,525 matched patients reported lower odds of stroke, myocardial infarction, atrial fibrillation and other cardiovascular events for Inspire therapy versus CPAP.
4. PREDICTOR Study Implications
The PREDICTOR study identified body mass index and neck circumference as reliable predictors of complete concentric collapse in OSA patients, suggesting many candidates can bypass drug-induced sleep endoscopy. This approach could decrease diagnostic costs, shorten time to therapy and broaden patient access to hypoglossal nerve stimulation.
